Abstract
Background We present a deep learning (DL)-based automated whole lung and COVID-19 pneumonia infectious lesions (COLI-Net) detection and segmentation from chest CT images.
Methods We prepared 2358 (347’259, 2D slices) and 180 (17341, 2D slices) volumetric CT images along with their corresponding manual segmentation of lungs and lesions, respectively, in the framework of a multi-center/multi-scanner study. All images were cropped, resized and the intensity values clipped and normalized. A residual network (ResNet) with non-square Dice loss function built upon TensorFlow was employed. The accuracy of lung and COVID-19 lesions segmentation was evaluated on an external RT-PCR positive COVID-19 dataset (7’333, 2D slices) collected at five different centers. To evaluate the segmentation performance, we calculated different quantitative metrics, including radiomic features.
Results The mean Dice coefficients were 0.98±0.011 (95% CI, 0.98-0.99) and 0.91±0.038 (95% CI, 0.90-0.91) for lung and lesions segmentation, respectively. The mean relative Hounsfield unit differences were 0.03±0.84% (95% CI, −0.12 – 0.18) and −0.18±3.4% (95% CI, −0.8 - 0.44) for the lung and lesions, respectively. The relative volume difference for lung and lesions were 0.38±1.2% (95% CI, 0.16-0.59) and 0.81±6.6% (95% CI, −0.39-2), respectively. Most radiomic features had a mean relative error less than 5% with the highest mean relative error achieved for the lung for the Range first-order feature (- 6.95%) and least axis length shape feature (8.68%) for lesions.
Conclusion We set out to develop an automated deep learning-guided three-dimensional whole lung and infected regions segmentation in COVID-19 patients in order to develop fast, consistent, robust and human error immune framework for lung and pneumonia lesion detection and quantification.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Swiss National Science Foundation under grant SNRF 320030_176052.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This retrospective study was conducted with institutional review board approval by SBMU, IR.SBMU.RETECH.REC.1399.393. Formal written consent was waived owing to the nature of the study
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
First Author: Isaac Shiri, MSc, Geneva University Hospital, Division of Nuclear Medicine and Molecular Imaging, CH-1211 Geneva, Switzerland, Email: Isaac.shirilord{at}unige.ch
Data Availability
Part of data is available in mentioned link.